The National Stock Exchange will admit equity shares of five companies for trading from September 1, 2026, marking a significant addition to India's primary market. According to NSE announcements, the companies span multiple sectors including healthcare, technical engineering, pharma, aviation services, and textiles. Hy-Tech Engineers Limited has been listed in the BE series under the trade-for-trade segment, where every transaction will require mandatory settlement. ABH Healthcare Limited will be listed in the ST series with symbol ABH and ISIN INE1R2M01019, while Madhur Knit Crafts Limited will also be in the ST series with symbol MADHURKNIT and ISIN INE1P5601010. Symbiotec Pharmalab Limited will be listed in the EQ series with symbol SYMBIOTEC and ISIN INE899I01028, and Skyways Air Services Limited will be in the EQ series with symbol SKYWAYS and ISIN INE0PX301025. As per NSE announcements, some shares will also be placed in the surveillance or trade-for-trade arrangements, which will restrict speculative intraday activities and may impact liquidity and price discovery during initial trading.
Hy-Tech Engineers emerged as the standout performer among Tuesday's market debuts, hitting the upper circuit limit of ₹78.75 and trading 48.58% higher than its issue price. According to reports from The Hindu BusinessLine and The Economic Times, the hydraulic fitting manufacturer listed at ₹72 on BSE, representing a 35.84% premium over the issue price of ₹53. At NSE, the stock debuted at ₹75, achieving a 41.50% premium. The strong performance was driven by the company's healthy financial metrics, with 22% operating margins and more than 11.5% net margins, supported by its own forging unit in Nashik. As per The Hindu BusinessLine, the stock was locked in its upper circuit of ₹78.75 and traded at ₹75.59 on both exchanges. The company's ₹135.51 crore free-float market capitalisation reflects strong investor confidence in the hydraulic fitting manufacturer.
Symbiotec Pharmalab made a muted market debut but demonstrated strong recovery potential. As reported by The Hindu BusinessLine, the pharma and biotech company started trading at ₹978.20 on BSE, down 0.99% from the issue price of ₹988. At NSE, it listed at par with the issue price at ₹988. However, shares later rose to ₹1,165 on NSE after hitting an intraday high of ₹1,180, representing a 17.81% gain from the IPO price. The company operates as a global leader in corticosteroid and steroidal-hormone APIs, though it trades at a premium 57x P/E compared to its ROE of 11.2% and ROCE of 11.6%. According to The Hindu BusinessLine, Shivani Nyati from Swastika Investmart Ltd. noted that the flat listing reflected muted market interest at the valuation, with the ₹1,757 crore issue largely an OFS by promoters and PE investors. Symbiotec Pharmalab closed at ₹1,095.95, a 10.93% premium over its issue price, pushing its ₹2,193.02 crore free-float market capitalisation to new heights.
Skyways Air Services faced initial listing challenges but showed signs of recovery. According to The Hindu BusinessLine and The Economic Times, the air freight forwarding company listed at a 10% discount against the issue price of ₹138, beginning trading at ₹124 on both BSE and NSE. However, the stock later rose nearly 4% to trade at ₹128.40 per share. The company maintains its position as the No. 1 player in air freight forwarding for four years running, though thin profit margins of around 2.26% make it sensitive to cargo rates and fuel costs. ₹216.79 crore of the fresh capital raised will be used for debt reduction, which should improve profits from FY27 onwards. As per The Hindu BusinessLine, Nyati noted that the weak listing showed sentiment was soft despite strong IPO demand, with allotted investors advised to hold only if comfortable waiting for the debt-reduction story to play out. Skyways Air Services closed at ₹125.65, an 8.95% discount to its issue price, bringing its ₹376.74 crore free-float market capitalisation to current levels.
The three companies' IPOs showed varied investor response with Hy-Tech Engineers leading in subscription at 244.41 times, followed by Symbiotec Pharmalab at 71.26 times and Skyways Air Services at 71.25 times. According to The Hindu BusinessLine and The Economic Times, Hy-Tech Engineers' ₹135.73 crore IPO had a price band of ₹50-53 per share, while Skyways' ₹138 crore IPO was priced at ₹131-138 per share. Symbiotec's ₹1,757 crore IPO comprised a fresh issue of ₹150 crore and an OFS of ₹1,607 crore, with the price band fixed at ₹938-988 per share. The strong subscription levels were led by Qualified Institutional Buyers, with significant participation from Non-Institutional and retail investors across all three offerings. The upcoming September 1 listings will include shares in the ST and trade-for-trade arrangements, which generally restrict speculative intraday activity and may impact liquidity during initial trading.
